Targeting Aberrant Signaling in Myeloid Malignancies
| Autor: | Rob S. Sellar, Julie-Aurore Losman |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Myeloid biology Kinase medicine.drug_class business.industry breakpoint cluster region Hematology medicine.disease Tyrosine-kinase inhibitor 03 medical and health sciences Leukemia 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure Oncology hemic and lymphatic diseases 030220 oncology & carcinogenesis biology.protein medicine Cancer research Signal transduction business Calreticulin Tyrosine kinase |
| Zdroj: | Hematology/Oncology Clinics of North America. 31:565-576 |
| ISSN: | 0889-8588 |
| Popis: | Clonal myeloid disorders are characterized by genetic alterations that activate cytokine signaling pathways and stimulate cell proliferation. These activated signaling pathways have been extensively studied as potential therapeutic targets, and tyrosine kinase inhibitors have indeed had extraordinary success in treating BCR/ABL-positive chronic myeloiud leukemia. However, although inhibitors of other activated kinases have been developed that perform well in preclinical studies, the therapeutic efficacy of these drugs in patients has been unimpressive. This article discusses potential reasons for these discordant results and outlines recent scientific advances that are informing future efforts to target activated kinases in clonal myeloid disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|